10-KPeriod: FY2006

PFIZER INC Annual Report, Year Ended Dec 31, 2006

Filed March 1, 2007For Securities:PFE

Summary

Pfizer Inc.'s 2006 Form 10-K report highlights a robust global pharmaceutical business, which constituted over 93% of its total revenues. The company demonstrated strong performance from its leading prescription medicines, including blockbuster drugs like Lipitor and Norvasc, each generating over $2 billion in revenue. Significant new product launches in 2006, such as Chantix/Champix for smoking cessation and Exubera for diabetes, signal continued investment in innovation and pipeline development. The company also completed a major strategic divestiture, selling its Consumer Healthcare business to Johnson & Johnson for $16.6 billion, allowing for a greater focus on its core pharmaceutical and animal health segments. Despite overall strength, Pfizer faces significant headwinds including patent expirations for key products like Zoloft and Zithromax, leading to increased generic competition. The company is also navigating a complex regulatory and pricing environment, particularly concerning managed care organizations and government healthcare programs like Medicare Part D. Pfizer's substantial investment in research and development, amounting to $7.6 billion in 2006, underscores its commitment to future growth through innovation, though drug development remains a long, expensive, and unpredictable process.

Key Highlights

  • 1Pfizer's Pharmaceutical segment remains the world's largest, contributing 93.2% of total 2006 revenues ($45.1 billion).
  • 2Blockbuster drugs like Lipitor ($12.9 billion) and Norvasc were significant revenue drivers, with nine pharmaceutical products each exceeding $1 billion in sales.
  • 3The company divested its Consumer Healthcare business to Johnson & Johnson for $16.6 billion in December 2006, refocusing on core pharmaceutical and animal health operations.
  • 4Key new product launches in 2006 included Chantix/Champix (smoking cessation) and Exubera (inhaled insulin therapy).
  • 5Significant R&D investment of $7.6 billion in 2006 demonstrates a commitment to innovation and future product pipeline development.
  • 6Pfizer faces increasing competition from generic drug manufacturers due to upcoming and recent patent expirations for major products like Zoloft and Zithromax.
  • 7The company is navigating complex government regulations and pricing pressures, particularly from managed care organizations and Medicare Part D.

Frequently Asked Questions

Pfizer's primary revenue drivers in 2006 were its Pharmaceutical segment, which accounted for over 93% of total revenue, and its leading prescription medicines. Key contributors included Lipitor, Norvasc, Zoloft, Lyrica, Celebrex, Viagra, Detrol/Detrol LA, Xalatan/Xalacom, and Zyrtec, with Lipitor alone generating $12.9 billion in sales.

In 2006, Pfizer completed the sale of its Consumer Healthcare business to Johnson & Johnson for $16.6 billion, a strategic move to sharpen its focus on its core pharmaceutical and animal health businesses. The company also launched new products like Chantix/Champix and Exubera.

The primary risks identified include increasing generic competition due to patent expirations for key products (e.g., Zoloft, Zithromax), challenges to existing patents for major drugs like Lipitor and Celebrex, and ongoing governmental and managed care pressures on drug pricing and access. The company also faces risks related to the lengthy and uncertain process of drug development and regulatory approval.

Pfizer invested $7.6 billion in research and development in 2006, demonstrating a strong commitment to innovation. The company is actively managing a pipeline of 249 projects in development, including 177 new molecular entities, and employs various strategies such as internal research, collaborations, and acquisitions to bring new products to market. However, it acknowledges that drug discovery and development are time-consuming, expensive, and unpredictable.